RespireRx Pharmaceuticals Inc. (RSPI)

Market Cap	1.71M +145.1%
Revenue (ttm)	n/a
Net Income	-2.17M
EPS	-0.01
Shares Out	949.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,300
Average Volume	83,730
Open	0.0018
Previous Close	0.0018
Day's Range	0.0018 - 0.0018
52-Week Range	0.0001 - 0.0027
Beta	0.61
RSI	55.59
Earnings Date	Nov 17, 2025

About RespireRx Pharmaceuticals

RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 2
• Stock Exchange: OTCMKTS
• Ticker Symbol: RSPI